Press Release

MOLOGEN AG: Large block trade of shares

Berlin, 2004-06-03

In an off market transaction, Mercury Investments, Limited has acquired 677,583 shares of MOLOGEN AG, Berlin, equalling 13,26% of the shares outstanding.

Mercury Investments is an international investment fund that focuses on identifying and investing in undervalued biotech companies with promising products and technologies. Andrew Kennedy, a spokesman for Mercury Investments, said, "Based on a combination of Mologen's current market valuation and the potential of its product portfolio and existing technologies, we believe the company represents a very exciting investment opportunity"

The package was sold by Mr Winfried Lange, who has been acting as a business angel for MOLOGEN in the years 1996 until 1998. "We have to thank Mr Lange for many years of trustful co-operation. We now have attracted a strong and experienced group of international investors with focus on the Biotech Industry and excellent knowledge of the European capital markets. This supports our vision to establish MOLOGEN internationally as the pacemaker in DNA-based medicine", Prof. Wittig, CEO and founder of MOLOGEN, commented.

MOLOGEN received the corresponding notifications with reference to May 28, 2004, according to §21 (1) WpHG (German Securities Trade Act) from the new shareholder Mercury Investments, Limited, and from Mr Lange. Mr Lange notified that he does not own any more shares of MOLOGEN.



MOLOGEN is focused on using its proprietary DNA technologies in the creation and development of treatment for high-unmet-need illnesses. Included are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases. MOLOGEN is currently in the process of approaching biotechnology and pharmaceutical companies in order to form development and commercial alliances to bring its products to the market more quickly and efficiently.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.


Contact: Matthias Reichel
Phone: +49-30-84 17 88 - 0
Fax: +49-30-84 17 88 - 50
e-mail: [email protected]